Background: Patients with unstable CAD encompass a heterogeneous group that varies widely regarding severity of the underlying coronary artery disease, prognosis and response to treatment. Patients with the highest risk of subsequent events usually have the largest benefit of an intensified pharmacological treatment and early mechanical intervention. Therefore, risk stratification is essential and should be initiated early and updated continuously throughout the hospital stay. Early risk stratification is usually performed by the use of clinical presentation, electrocardiography, and biochemical markers of myocardial damage. Levels of natriuretic peptides have been shown to reflect cardiac performance and there is emerging role of these peptides in the early risk stratification of unstable CAD patients. Aim of the study: The aim of the study was to examine whether measuring of brain natriuretic peptide (BNP) improves the ability to identify high-risk patients with UA/NSTEMI who will benefit from an early invasive strategy.Conclusion: The present study found that there is trend toward higher mortality with increasing levels of BNP (by quartile) but this trend was not statistically significant.